Insight

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah and Vania Hungria

Oct 26, 2024, 12:33

Al-Ola A Abdallah: Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?

Al-Ola A Abdallah, Associate Professor, Plasma Cell disorder program Director, Division of HMCT at University of Kansas Medical Center, shared an article by Vania Hungria, Department of hematology at Santa Casa de São Paulo, on X:

” Will we soon see Belantamab back in relapse myeloma as part of a combination therapy?”

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Authors: Vania Hungria, Pawel Robak, Marek Hus, Vera Zherebtsova, Christopher Ward, P. Joy Ho, D.Phil and Ana Carolina Ribas de Almeida

Al-Ola A Abdallah

Al-Ola A Abdallah Ana Carolina Ribas de Almeida cancer Christopher Ward combination therapy D.Phil Marek Hus Myeloma OncoDaily Oncology P. Joy Ho Pawel Robak Santa Casa de São Paulo University of Kansas Medical Center Vania Hungria Vera Zherebtsova

NEW PAPER ALERT: Efficacy of CDK4/6 Inhibitors and Endocrine Therapy in HR+/HER2- Advanced Breast Cancer by PAM50 Subtype: SOLTI-1801 CDK-PREDICT Results

Oncologist Near Me – Fabrice André: Leading Expert in Breast Cancer

Funding Impactful Cancer Research That Might Otherwise Go Unsupported: Ryan Schoenfeld on the Secret Behind Mark Foundation’s Success

One Hand Gives, Another Takes? Trump, Musk, Congress and Childhood Cancer Research Funding

Fabrice André has been elected as the President of the ESMO for the term 2025-2026

Special Coverage